Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel
NASDAQ:MREO

Mereo BioPharma Group Q3 2026 Earnings Date & Estimates

Mereo BioPharma Group logo
$0.32 -0.03 (-7.97%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Mereo BioPharma Group is expected to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 10, 2026 at 2:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
2:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Mereo BioPharma Group in Q3 2026

Mereo BioPharma Group is expected to post earnings of -$0.01 per share on revenue of $4.61 million. In the same quarter a year earlier Mereo BioPharma Group reported -$0.01 per share. Mereo BioPharma Group last reported on August 12, 2026, posting -$0.01 per share and matching the -$0.01 consensus estimate. Mereo BioPharma Group has beaten the consensus EPS estimate in 0 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.01
Expected Revenue
$4.61 million
Prior-Year EPS
-$0.01

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.01 (Met Expectations)
EPS Beat Rate
0 of last 8 quarters

Prepare for the Q3 2026 Call

Mereo BioPharma Group Q3 2026 Earnings FAQ

Mereo BioPharma Group (NASDAQ:MREO) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Mereo BioPharma Group's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 2:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Mereo BioPharma Group to post earnings of -$0.01 per share for Q3 2026.

The consensus revenue estimate for Mereo BioPharma Group is $4.61 million for Q3 2026.

Mereo BioPharma Group Earnings Headlines

Mereo BioPharma Group plc - Sponsored ADR (MREO) - What Are Researchers Thinking About This Stock?
October 12 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109304
Mereo BioPharma Group plc(NasdaqCM:MREO) dropped from S&P Global BMI Index
September 22, 2026  |  marketscreener.comM
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 12 at 1:00 AM  |  Weiss Ratings (Ad)
Mereo BioPharma Group PLC ADR
September 6, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/mreo/stock-grader?gaa_at=eafs&gaa_n=AWEtsqc6B9yx7zkFtXeVdyh8sUL6a0NHaZpikox_gE8CyfVWSNS14FAY3yRm&gaa_sig=kHC6aooPAYbzCI7W6oBCJm9TdPvP0zjscQlgulM6WjfVnqdNsGS8SgtfPIXket1fux89jsCNYJidn0qvZE0Bgw%25253D%25253D&gaa_ts=6971995f
Mereo BioPharma Group plc: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung ...
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69276682-mereo-biopharma-group-plc-mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-for-alvelestat-in-alpha-1-antitrypsin-defici-399.htm
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/mereo-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-highlights-1036440730
See More Mereo BioPharma Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email.

About Mereo BioPharma Group

Mereo BioPharma Group (NASDAQ:MREO) plc is a clinical-stage biopharmaceutical company focused on developing medicines for rare diseases and other serious conditions with limited treatment options. The company’s activities include drug discovery, clinical development and commercialization through partnerships with larger pharmaceutical companies.

Mereo’s pipeline has included setrusumab, an investigational anti-sclerostin antibody being developed for osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones. The company has also developed alvelestat, an oral neutrophil elastase inhibitor being evaluated for diseases associated with excessive neutrophilic inflammation, including severe alpha-1 antitrypsin deficiency-associated lung disease and bronchiectasis.

Founded in 2015, Mereo is headquartered in London and conducts development activities through international clinical and commercial collaborations. Its shares trade on the Nasdaq Capital Market under the symbol MREO.

View Mereo BioPharma Group Profile
Earnings Tools